Učitavanje...
Outcome of COVID-19 patients with use of Tocilizumab: A single center experience
COVID-19 pandemic has become a global concern. Cytokine release syndrome (CRS) complicates acute respiratory distress syndrome (ARDS) and causes multi-organ failure which can subsequently lead to mortality in COVID-19 patients. Tocilizumab, an interleukin-6 antagonist, has shown to salvage patients...
Spremljeno u:
| Izdano u: | Int Immunopharmacol |
|---|---|
| Glavni autori: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Elsevier B.V.
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7455148/ https://ncbi.nlm.nih.gov/pubmed/32889236 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.intimp.2020.106926 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|